<DOC>
	<DOCNO>NCT02220738</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability pharmacokinetics multiple dos ABT-957 subject mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics ABT-957 Subjects With Mild-to-Moderate Alzheimer 's Disease Stable Doses Acetylcholinesterase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Meets National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association criterion probable Alzheimer 's disease ( AD ) ; Has MiniMental State Examination total score 16 26 ; Has Modified Hachinski Ischemia Scale score â‰¤ 4 ; Is take stable dose donepezil , galantamine rivastigmine least 30 day ; Has computerize tomography magnetic resonance imaging . The scan must show evidence alternative etiology dementia ; With exception diagnosis mildtomoderate AD presence stable medical condition , general good health . Positive screen drug abuse , alcohol cotinine ; Females must positive result pregnancy ; Focal neurological sign examination ; Has clinically significant abnormal value , serum chemistry , hematology urinalysis ; History significant neurologic disease AD ; History head trauma , motor vehicle accident , concussion .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>